clinical trial · NCT05598320
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
Ascendis Pharma Growth Disorders A/S·phase3·completed·n = 84
AchondroplasiaNavepegritide (TransCon CNP)Placebo for Navepegritide (TransCon CNP)
brief summary
The purpose of this clinical trial was to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of 100 µg TransCon CNP/kg compared to placebo on Annualized Growth Velocity after a 52-week randomized treatment period in children aged 2 to 11 years with genetically confirmed Achondroplasia. The double-blind, placebo-controlled treatment period was followed by an Open Label Extension (OLE) period of a 52-week duration.
started
Mar 3, 2023
primary completion
Aug 9, 2024
completion
Aug 13, 2025
last updated
Jul 14, 2026
official title
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension Period
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol